{"id":"W4377944155","doi":"10.1016/j.jtho.2023.05.015","title":"Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Astellas Pharma; Yuhan; BeiGene; G1 Therapeutics; Pfizer; Genentech; American Association for Cancer Research; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Discontinuation; Osimertinib; Tolerability; Placebo; Internal medicine; Adverse effect; Oncology; Surgery; Cancer; Adenocarcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001849133,0.0001702729,0.001757618,0.0004878453,0.00006648204,0.000007841121,0.0001464456,0.0001222576,0.0001830141],"category_scores_gemma":[0.0006590938,0.0000977918,0.0001873264,0.001832069,0.0001246873,0.00008490316,0.00006818272,0.0003253314,0.000001865895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003587933,"about_ca_system_score_gemma":0.001035492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003681653,"about_ca_topic_score_gemma":0.003964938,"domain_scores_codex":[0.9963289,0.0006067436,0.002084115,0.0002315283,0.0005076257,0.0002410729],"domain_scores_gemma":[0.9965527,0.00063274,0.001664766,0.000328319,0.0005799246,0.0002415462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1406263,0.002260418,0.8361096,0.00003891026,0.004237574,0.00002691376,0.002326023,0.0003392834,0.0001218282,0.000007362071,0.0003565049,0.01354931],"study_design_scores_gemma":[0.05796281,0.007699741,0.9315937,0.00008815664,0.001444103,0.000001024763,0.0008096612,0.0001296951,0.00004344011,0.00006040255,0.00008838951,0.00007886971],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884947,0.0001420097,0.00009163416,0.009538143,0.0001803762,0.001099465,0.0004002841,0.00001455733,0.00003881589],"genre_scores_gemma":[0.998825,0.0000262103,0.0005049329,0.0002745569,0.00002894637,0.000009844276,0.0002769473,0.00001539164,0.00003814472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09548413,"threshold_uncertainty_score":0.5565583,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05695210664319922,"score_gpt":0.4782207666485358,"score_spread":0.4212686600053366,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}